We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Desktop Genetics Receives Strategic Investment from Illumina

Desktop Genetics Receives Strategic Investment from Illumina

Desktop Genetics Receives Strategic Investment from Illumina

Desktop Genetics Receives Strategic Investment from Illumina

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Desktop Genetics Receives Strategic Investment from Illumina"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Desktop Genetics Ltd has announced that it has received investment funding from Illumina, Inc., the global leader in next-generation sequencing (NGS) technology. The investment will be used to fund the continued development and commercialization of the DESKGEN platform with a particular focus on integration with NGS pipelines.

The investment from Illumina follows DTG's recent fundraising from a syndicate of venture capitalists and angel investors. This combined funding is being used to continue developing DTG's proprietary DESKGEN genome editing software platform and core CRISPR algorithms. DTG is also investing in the expansion of its existing sales infrastructure and expanding marketing efforts to drive adoption of the technology across the industry.

The DESKGEN platform makes CRISPR gene editing more predictable, accessible and efficient, providing scientists with the capabilities they need to scale their genomics research. Users are walked through every step of the CRISPR gene editing process with a suite of lab-validated algorithms derived from leading peer-reviewed research and industry expertise.

With DESKGEN, researchers can access the latest advances, algorithms and expertise in CRISPR gene editing as new techniques are invented, enhancing their productivity and reducing the time and cost of gene editing.

Through partnerships with specialist service-providers including Transcriptic and Horizon Discovery, DTG offers CRISPR library design, synthesis and screening services, for high-throughput cell line engineering services in the cloud. To date, the DESKGEN platform has enabled over 2,000 gene editing experiments and has driven thousands of users to design and access the optimal reagents for their research.

Riley Doyle, CEO of DTG, commented: "We are delighted that Illumina has decided to invest in DTG, in recognition of the value our DESKGEN platform and software development expertise can add to CRISPR-based genome editing programs and next-generation sequencing applications."

Nicholas Naclerio, Ph.D., SVP of Corporate and Venture Development at Illumina, commented: "We have been impressed by DTG's proprietary DESKGEN platform for CRISPR-based gene editing. CRISPR is becoming increasingly important for NGS applications, and we are pleased to support DTG in executing their vision to build this market."